Literature DB >> 30896450

RhoBTB1 protects against hypertension and arterial stiffness by restraining phosphodiesterase 5 activity.

Masashi Mukohda1, Shi Fang1,2, Jing Wu1,2, Larry N Agbor1, Anand R Nair1, Stella-Rita C Ibeawuchi1, Chunyan Hu1, Xuebo Liu1, Ko-Ting Lu1,2, Deng-Fu Guo1, Deborah R Davis1, Henry L Keen1, Frederick W Quelle1, Curt D Sigmund1,2.   

Abstract

Mice selectively expressing PPARγ dominant negative mutation in vascular smooth muscle exhibit RhoBTB1-deficiency and hypertension. Our rationale was to employ genetic complementation to uncover the mechanism of action of RhoBTB1 in vascular smooth muscle. Inducible smooth muscle-specific restoration of RhoBTB1 fully corrected the hypertension and arterial stiffness by improving vasodilator function. Notably, the cardiovascular protection occurred despite preservation of increased agonist-mediated contraction and RhoA/Rho kinase activity, suggesting RhoBTB1 selectively controls vasodilation. RhoBTB1 augmented the cGMP response to nitric oxide by restraining the activity of phosphodiesterase 5 (PDE5) by acting as a substrate adaptor delivering PDE5 to the Cullin-3 E3 Ring ubiquitin ligase complex for ubiquitination inhibiting PDE5. Angiotensin-II infusion also caused RhoBTB1-deficiency and hypertension which was prevented by smooth muscle specific RhoBTB1 restoration. We conclude that RhoBTB1 protected from hypertension, vascular smooth muscle dysfunction, and arterial stiffness in at least two models of hypertension.

Entities:  

Keywords:  Hypertension; Vascular Biology

Year:  2019        PMID: 30896450      PMCID: PMC6546477          DOI: 10.1172/JCI123462

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  58 in total

1.  FDA eases restrictions on the glucose-lowering drug rosiglitazone.

Authors:  Mike Mitka
Journal:  JAMA       Date:  2013-12-25       Impact factor: 56.272

Review 2.  Transcriptional Regulation of Adipogenesis.

Authors:  Paula Mota de Sá; Allison J Richard; Hardy Hang; Jacqueline M Stephens
Journal:  Compr Physiol       Date:  2017-03-16       Impact factor: 9.090

3.  Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities.

Authors:  J D Corbin; I V Turko; A Beasley; S H Francis
Journal:  Eur J Biochem       Date:  2000-05

4.  Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma.

Authors:  Quy N Diep; Mohammed El Mabrouk; Jeffrey S Cohn; Dierk Endemann; Farhad Amiri; Agostino Virdis; Mario Fritsch Neves; Ernesto L Schiffrin
Journal:  Circulation       Date:  2002-05-14       Impact factor: 29.690

5.  Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling.

Authors:  Andreas M Beyer; Gary L Baumbach; Carmen M Halabi; Mary L Modrick; Cynthia M Lynch; Thomas D Gerhold; Shams M Ghoneim; Willem J de Lange; Henry L Keen; Yau-Sheng Tsai; Nobuyo Maeda; Curt D Sigmund; Frank M Faraci
Journal:  Hypertension       Date:  2008-02-19       Impact factor: 10.190

6.  Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle.

Authors:  Weimin He; Yaacov Barak; Andrea Hevener; Peter Olson; Debbie Liao; Jamie Le; Michael Nelson; Estelita Ong; Jerrold M Olefsky; Ronald M Evans
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-05       Impact factor: 11.205

7.  Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet.

Authors:  Andreas M Beyer; Willem J de Lange; Carmen M Halabi; Mary L Modrick; Henry L Keen; Frank M Faraci; Curt D Sigmund
Journal:  Circ Res       Date:  2008-07-31       Impact factor: 17.367

Review 8.  Rho GTPases of the RhoBTB subfamily and tumorigenesis.

Authors:  Jessica Berthold; Kristina Schenkova; Francisco Rivero
Journal:  Acta Pharmacol Sin       Date:  2008-03       Impact factor: 6.150

9.  Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities.

Authors:  Lynn M Boyden; Murim Choi; Keith A Choate; Carol J Nelson-Williams; Anita Farhi; Hakan R Toka; Irina R Tikhonova; Robert Bjornson; Shrikant M Mane; Giacomo Colussi; Marcel Lebel; Richard D Gordon; Ben A Semmekrot; Alain Poujol; Matti J Välimäki; Maria E De Ferrari; Sami A Sanjad; Michael Gutkin; Fiona E Karet; Joseph R Tucci; Jim R Stockigt; Kim M Keppler-Noreuil; Craig C Porter; Sudhir K Anand; Margo L Whiteford; Ira D Davis; Stephanie B Dewar; Alberto Bettinelli; Jeffrey J Fadrowski; Craig W Belsha; Tracy E Hunley; Raoul D Nelson; Howard Trachtman; Trevor R P Cole; Maury Pinsk; Detlef Bockenhauer; Mohan Shenoy; Priya Vaidyanathan; John W Foreman; Majid Rasoulpour; Farook Thameem; Hania Z Al-Shahrouri; Jai Radhakrishnan; Ali G Gharavi; Beatrice Goilav; Richard P Lifton
Journal:  Nature       Date:  2012-01-22       Impact factor: 49.962

10.  Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.

Authors:  David B Savage; Garry D Tan; Carlo L Acerini; Susan A Jebb; Maura Agostini; Mark Gurnell; Rachel L Williams; A Margot Umpleby; E Louise Thomas; Jimmy D Bell; Adrian K Dixon; Fidelma Dunne; Romina Boiani; Saverio Cinti; Antonio Vidal-Puig; Fredrik Karpe; V Krishna K Chatterjee; Stephen O'Rahilly
Journal:  Diabetes       Date:  2003-04       Impact factor: 9.461

View more
  15 in total

1.  Conditional deletion of smooth muscle Cullin-3 causes severe progressive hypertension.

Authors:  Larry N Agbor; Anand R Nair; Jing Wu; Ko-Ting Lu; Deborah R Davis; Henry L Keen; Frederick W Quelle; James A McCormick; Jeffrey D Singer; Curt D Sigmund
Journal:  JCI Insight       Date:  2019-06-11

Review 2.  Report of the National Heart, Lung, and Blood Institute Working Group on Hypertension: Barriers to Translation.

Authors:  Curt D Sigmund; Robert M Carey; Lawrence J Appel; Donna K Arnett; Hayden B Bosworth; William C Cushman; Zorina S Galis; Melissa Green Parker; John E Hall; David G Harrison; Alicia A McDonough; Holly L Nicastro; Suzanne Oparil; John W Osborn; Mohan K Raizada; Jacqueline D Wright; Young S Oh
Journal:  Hypertension       Date:  2020-02-17       Impact factor: 10.190

Review 3.  Cullin-3: Renal and Vascular Mechanisms Regulating Blood Pressure.

Authors:  Jing Wu; James A McCormick; Curt D Sigmund
Journal:  Curr Hypertens Rep       Date:  2020-08-27       Impact factor: 5.369

4.  Robust Performance of Potentially Functional SNPs in Machine Learning Models for the Prediction of Atorvastatin-Induced Myalgia.

Authors:  Brandon N S Ooi; Ariel F Ying; Yong Zher Koh; Yu Jin; Sherman W L Yee; Justin H S Lee; Samuel S Chong; Jack W C Tan; Jianjun Liu; Caroline G Lee; Chester L Drum
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

Review 5.  Anti-inflammatory mechanisms of the vascular smooth muscle PPARγ.

Authors:  Masashi Mukohda; Hiroshi Ozaki
Journal:  J Smooth Muscle Res       Date:  2021

6.  Comorbidities Caused by a Corrupt Cullin 3: Lessons Learned From Bedside to Bench.

Authors:  Jing Wu; Curt D Sigmund
Journal:  Hypertension       Date:  2021-12-08       Impact factor: 10.190

Review 7.  Redox Switches Controlling Nitric Oxide Signaling in the Resistance Vasculature and Implications for Blood Pressure Regulation: Mid-Career Award for Research Excellence 2020.

Authors:  Atinuke Aramide Modupe Dosunmu-Ogunbi; Joseph C Galley; Shuai Yuan; Heidi M Schmidt; Katherine C Wood; Adam C Straub
Journal:  Hypertension       Date:  2021-08-23       Impact factor: 9.897

8.  EP3 (E-Prostanoid 3) Receptor Mediates Impaired Vasodilation in a Mouse Model of Salt-Sensitive Hypertension.

Authors:  Jing Wu; Shi Fang; Ko-Ting Lu; Kelsey Wackman; Michal L Schwartzman; Sergey I Dikalov; Justin L Grobe; Curt D Sigmund
Journal:  Hypertension       Date:  2021-03-01       Impact factor: 9.897

Review 9.  PPARγ and RhoBTB1 in hypertension.

Authors:  Shi Fang; Curt D Sigmund
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-03       Impact factor: 3.416

Review 10.  Role of the Peroxisome Proliferator Activated Receptors in Hypertension.

Authors:  Shi Fang; M Christine Livergood; Pablo Nakagawa; Jing Wu; Curt D Sigmund
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 23.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.